---
title: "Omeros | 8-K: FY2026 Q1 Revenue: USD 9.893 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286310910.md"
datetime: "2026-05-13T20:16:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286310910.md)
  - [en](https://longbridge.com/en/news/286310910.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286310910.md)
---

# Omeros | 8-K: FY2026 Q1 Revenue: USD 9.893 M

Revenue: As of FY2026 Q1, the actual value is USD 9.893 M.

EPS: As of FY2026 Q1, the actual value is USD 0.62.

EBIT: As of FY2026 Q1, the actual value is USD -13 M.

#### Segment Revenue

奥麦罗制药 (Omeros Corporation) launched YARTEMLEA® in the U.S. market in January 2026. During the first quarter of 2026, gross product sales were $11.1 million, and associated net sales were $9.9 million after deductions.

#### Operational Metrics

-   **Net Income (Loss)**: For the first quarter of 2026, net income was $56.1 million, or $0.78 per share, significantly improving from a net loss of - $33.5 million, or - $0.58 per share, for the first quarter of 2025.
-   **Non-GAAP Adjusted Net Loss**: Excluding a $73.1 million non-cash gain, the non-GAAP adjusted net loss for the three months ended March 31, 2026, was - $17.1 million, or - $0.24 per share.
-   **Loss from Operations**: Loss from operations for the first quarter of 2026 was - $17.421 million, compared to - $34.969 million for the first quarter of 2025.
-   **Total Operating Expenses**: Total operating expenses for the three months ended March 31, 2026, were $27.3 million, a decrease of $7.7 million from $35.0 million for the same period in 2025, primarily due to reduced OMS906-related research and development work.
-   **Interest Expense**: Interest expense increased by $2.2 million to $5.894 million for the three months ended March 31, 2026, from $3.654 million in the prior year period, mainly due to interest on the 2029 Notes.
-   **Interest and Other Income**: Interest and other income was $1.5 million for the first quarter of 2026, up from $1.1 million for the first quarter of 2025, attributed to higher cash and investment balances.
-   **Net Income from Discontinued Operations**: Net income from discontinued operations, net of tax, was $4.8 million, or $0.07 per share, for the three months ended March 31, 2026, compared to $4.1 million, or $0.07 per share, in the prior year period.

#### Cash and Investments

As of March 31, 2026, 奥麦罗制药 (Omeros Corporation) had $135.3 million in cash and short-term investments.

#### Debt

In February 2026, the remaining $17.1 million aggregate principal amount of the 2026 unsecured convertible notes was repaid at maturity. The only remaining debt outstanding is $70.8 million aggregate principal amount of the 2029 Notes, maturing in June 2029.

#### Share Repurchase

During the first quarter of 2026, 奥麦罗制药 (Omeros Corporation) repurchased and retired approximately 0.4 million shares of common stock at an average cost of $11.70 per share, for an aggregate purchase price of $4.2 million.

#### Outlook / Guidance

A marketing authorization application for YARTEMLEA is currently under review by the European Medicines Agency, with a decision expected in mid-2026. The U.S. Centers for Medicare & Medicaid Services assigned a permanent J-code specific for YARTEMLEA, effective July 1, 2026, and recommended approval of the New Technology Add-On Payment for YARTEMLEA, expected to be effective October 1, 2026. 奥麦罗制药 (Omeros Corporation) is also targeting the initiation of an in-patient clinical trial for OMS527 for cocaine use disorder by year-end 2026.

### Related Stocks

- [OMER.US](https://longbridge.com/en/quote/OMER.US.md)

## Related News & Research

- [There's A Lot To Like About OMER's (BIT:OMER) Upcoming €0.17 Dividend](https://longbridge.com/en/news/286365767.md)
- [Omeros Q1 net income turns positive after YARTEMLEA launch](https://longbridge.com/en/news/286310334.md)
- [Novo Nordisk Discloses Gifted Share Transactions Linked to CFO Associates](https://longbridge.com/en/news/286260366.md)
- [Assertio Terminates Garda Agreement, Agrees To $166.4 Mln Acquisition By Zydus Worldwide DMCC](https://longbridge.com/en/news/286261460.md)
- [Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights | ANRO Stock News](https://longbridge.com/en/news/286247939.md)